Health Canada approves CALQUENCE (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma (MCL)
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
MCL is an aggressive B-cell non-Hodgkin lymphoma (NHL) with poor prognosis.2?MCL accounts for approximately 5% to 10% of new NHL cases in Canada each year, with an annual incidence of 0.5 per 100,000 people in Western countries.2,6?The median age at diagnosis is 68 years, and occurs more often in men than women.6 While MCL patients initially respond to treatment, there is a high frequency of recurrence.6 About Calquence
Calquence (acalabrutinib; previously known as ACP-196) is a selective inhibitor of Bruton's tyrosine kinase (BTK). Calquence binds covalently to BTK, thereby inhibiting its activity, and has demonstrated this with minimal interactions with other immune cells in pre-clinical studies.1,4,5 In B cells, BTK signaling results in activation of pathways necessary for B cell proliferation, trafficking, chemotaxis and adhesion.1 The recommended dose of Calquence?is one 100mg capsule taken orally twice daily (approximately 12 hours apart), until disease progression or unacceptable toxicity.1 Calquence may be taken with or without food.1 About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of primary and specialty care medicines that transform lives. Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease; Oncology; and Respiratory, Inflammation and Autoimmunity. AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. In Canada, we employ more than 675 employees across the country and our headquarters are located in Mississauga, Ontario. For more information, please visit the company's website at www.astrazeneca.ca.
Approval of the highly selective Bruton's tyrosine kinase (BTK)
inhibitor in MCL marks AstraZeneca's entry into the treatment of blood cancers
MCL is an aggressive B-cell non-Hodgkin lymphoma (NHL) with poor prognosis.2?MCL accounts for approximately 5% to 10% of new NHL cases in Canada each year, with an annual incidence of 0.5 per 100,000 people in Western countries.2,6?The median age at diagnosis is 68 years, and occurs more often in men than women.6 While MCL patients initially respond to treatment, there is a high frequency of recurrence.6 About Calquence
Calquence (acalabrutinib; previously known as ACP-196) is a selective inhibitor of Bruton's tyrosine kinase (BTK). Calquence binds covalently to BTK, thereby inhibiting its activity, and has demonstrated this with minimal interactions with other immune cells in pre-clinical studies.1,4,5 In B cells, BTK signaling results in activation of pathways necessary for B cell proliferation, trafficking, chemotaxis and adhesion.1 The recommended dose of Calquence?is one 100mg capsule taken orally twice daily (approximately 12 hours apart), until disease progression or unacceptable toxicity.1 Calquence may be taken with or without food.1 About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of primary and specialty care medicines that transform lives. Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease; Oncology; and Respiratory, Inflammation and Autoimmunity. AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. In Canada, we employ more than 675 employees across the country and our headquarters are located in Mississauga, Ontario. For more information, please visit the company's website at www.astrazeneca.ca.